https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-01347-7 https://www.ncbi.nlm.nih.gov/pubmed/32907566?dopt=Abstract Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. Respir […]
AZD8871
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases
https://clinicaltrials.gov/ct2/show/NCT03645434?type=Intr&cond=COPD&phase=01234&lupd_s=10%2F25%2F2018&lupd_d=14&sort=nwst A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. Condition : Chronic Obstructive Pulmonary Disease Interventions : Drug: AZD8871; Drug: Anoro® Ellipta® Sponsors : AstraZeneca; Parexel Recruiting NCT03645434 Fri, 24 Aug 2018 12:00:00 EDT
